

A

- Abciximab, 379
- Acenocoumarol, 14
- Activated clotting time, 530-531
 - clinical applications of, 531
- Activated partial thromboplastin time (aPTT), 520
 - argatroban and, 525
 - bivalirudin and, 91
 - coagulation testing and, 520-521
 - direct thrombin inhibitors and, 92, 96, 97, 525-526
 - measurements between point-of-care and central lab, 517
 - transitioning to anti-Xa for heparin management, 638-640
 - unfractionated heparin and, 366-367, 370, 521-524
 - variables in, 514-515
- Activated protein C resistance
 - with factor V-deficient plasma, 556
 - testing, 563
 - treatment considerations, 566
- Activated prothrombin complex concentrates, 166, 202
- Activated thrombin time, 49
- Acute coronary syndrome
 - anticoagulant guidelines for, 371-375
 - anti-factor Xa activity with low molecular weight heparin, 370-371
 - aPTT and anti-factor Xa for unfractionated heparin, 366-367, 370
 - arterial femoral sheath and, 376
 - aspirin therapy in, 377
 - bivalirudin dosing in, 92
 - bivalirudin efficacy and, 385
 - bleeding in, 366, 369
 - diagnostic criteria for, 365
 - direct oral anticoagulants in, 385-386
 - dosing in, 258
 - dual antiplatelet therapy in, 383-384
 - electrocardiographic findings in, 364
 - epidemiology of, 363
 - glycoprotein IIb/IIIa inhibitors in, 379
 - heparin-induced thrombocytopenia, 442-443
 - injectable anticoagulant monitoring in, 376
 - major bleeding risk factors in, 371
 - pathophysiology of, 364
 - P2Y12 inhibitor in, 377
 - risk stratification for NSTEMI in, 366-369
 - signs of, 363, 365
 - symptoms of, 365
 - triple antithrombotic therapy in, 380-383
- Acute liver dysfunction, 19
- Acute spinal cord injury, 303, 304
- Agency for Healthcare Research and Quality, 612, 613
- Aggregation, 507
- Alere, 611
- Alteplase
 - catheter occlusion and, 114
 - deep vein thrombosis and, 112
 - frostbite and, 117
 - intracranial hemorrhage risk with, 122
 - ischemic stroke and, 113
 - mechanical circulatory support devices and, 116
 - peripheral arterial occlusion and, 114
 - pleural effusion/empyema and, 115
 - prosthetic heart valve thrombosis and, 116
 - pulmonary embolism and, 111

- ultrasound-facilitated, catheter directed, low-dose thrombolytics and, 117, 118-119
- See also Recombinant tissue plasminogen activator
- American College of Cardiology, 4, 587
 - evidence grades of, 7
- American College of Chest Physicians (ACCP), 4
 - anticoagulation recommended duration by, 340
 - atrial fibrillation stroke risk stratification by, 351
 - evidence grades of, 6
 - grading recommendations of, 450
 - guidelines of, 5, 271
 - platelet count monitoring by, 61, 427
 - venous thrombolytic embolism bleeding and, 340
- American College of Clinical Pharmacy, 610
- American College of Obstetrics and Gynecology, 450
- American Heart Association (AHA), 4, 587
 - evidence grades by, 7
 - grading recommendations of, 405
 - guidelines of, 5
- American Journal of Health-System Pharmacy*, 609
- American Pharmacists Association, Billing Boot Camp, 613
- American Society of Clinical Oncology, treatment guidelines of, 271
- American Society of Health-System Pharmacists (ASHP), 608, 610, 611, 613
 - guidelines, 5
- American Society of Hematology, 610
- Aminocaproic acid, 174, 180
- Amiodarone, cardioversion, 356
- Andexanet alfa, 139, 178-179, 200, 206, 209, 539
- Androgenic agents, 619
- Annals of Internal Medicine*, 609
- Annals of Pharmacotherapy*, 609
- Antiandrogens, 619
- Anticardiolipin antibodies, 554, 557
- Anticoagulant monitoring
 - in hospital setting, 582
 - injectable, 376
- Anticoagulants. See specific anticoagulants
- Anticoagulation Centers of Excellence, 577
- Anticoagulation Forum, 5, 577, 610, 611, 612
 - Boot Camp, 588
- Anticoagulation management service (AMS)
 - clinical endpoints for, 599-600
 - disease state protocols/guidelines for, 580-581
 - direct oral anticoagulants and, 593-595
 - electronic media care delivery in, 592
 - hospital setting standards of practice for, 581-583
 - in-clinic vs. telephonic care delivery in, 592
 - inpatient care structure in, 577-578
 - inpatient service hierarchy in, 579
 - inpatient standards of practice in, 578-580
 - INR in range and, 599
 - INR variability and, 598-599
 - lab vs point-of-care INR testing in, 591
 - nonadherence management in, 594
 - outpatient panel-based workload in, 589-590
 - outpatient structure in, 589
 - outpatient team-based workload in, 590
 - outpatient therapy and, 588-589
 - patient education and, 584, 586
 - patient self-testing, self-management and, 591-592
 - patient-centered care, shared decision making and, 587
 - pharmacist run vs. nurse run in, 590-591
 - provider training, competency in, 587, 588
 - quality improvement in, 584, 600-601
 - quality metrics for, 598
 - regulatory standards for, 583
 - standards of practice for, 595-597
 - time-in-therapeutic range in, 597-598
 - transitions of care and, 587
- Anticoagulation resources, 588
- Anticoagulation therapy
 - ACCP recommended duration for, 340
 - nutrition and, 623-624
 - restarting, 218-219